OBJECTIVES: To compare cervical concentrations of numerous cytokines/chemokines in women with bacterial vaginosis (BV) compared with the levels detected after BV resolution and determine if hormonal contraceptive use modulates the local inflammatory response to BV. METHODS: Cervical secretions from 81 women with BV at enrollment and normal flora at one-month follow-up were analysed for 10 different cytokines/chemokines using multiplexed fluorescent bead-based immunoassays. RESULTS: BV was associated with significantly higher concentrations of IL-1 beta, tumour necrosis factor (TNF), interferon-gamma, IL-2, IL-4, and IL-10 compared with the levels detected in the presence of normal vaginal flora. Analysis of results stratified by contraceptive practice demonstrated significantly lower levels of numerous cytokines among women with BV using hormonal contraceptives compared with those women with BV not using hormonal contraceptives. Hormonal contraceptive use was also associated with a statistically significant lesser change in TNF levels between the two study visits compared with the amount of change detected between visits among women who denied their use. CONCLUSIONS: Despite increases in the levels of both pro and anti-inflammatory cytokines in the lower genital tract of women with BV, the overall balance of these two types of molecules was maintained. The character of this local inflammatory response may help explain the typical absence of overt signs of inflammation among women with BV. In addition, hormonal contraceptive use was associated with significantly lower levels of the pro-inflammatory molecules TNF, interferon-gamma, and granulocyte macrophage colony-stimulating factor in women with BV, but did not significantly reduce the levels of IL-10, a key anti-inflammatory cytokine. These results suggest the possibility of an association between hormonal contraceptive use and altered genital tract immunity.
OBJECTIVES: To compare cervical concentrations of numerous cytokines/chemokines in women with bacterial vaginosis (BV) compared with the levels detected after BV resolution and determine if hormonal contraceptive use modulates the local inflammatory response to BV. METHODS: Cervical secretions from 81 women with BV at enrollment and normal flora at one-month follow-up were analysed for 10 different cytokines/chemokines using multiplexed fluorescent bead-based immunoassays. RESULTS: BV was associated with significantly higher concentrations of IL-1 beta, tumour necrosis factor (TNF), interferon-gamma, IL-2, IL-4, and IL-10 compared with the levels detected in the presence of normal vaginal flora. Analysis of results stratified by contraceptive practice demonstrated significantly lower levels of numerous cytokines among women with BV using hormonal contraceptives compared with those women with BV not using hormonal contraceptives. Hormonal contraceptive use was also associated with a statistically significant lesser change in TNF levels between the two study visits compared with the amount of change detected between visits among women who denied their use. CONCLUSIONS: Despite increases in the levels of both pro and anti-inflammatory cytokines in the lower genital tract of women with BV, the overall balance of these two types of molecules was maintained. The character of this local inflammatory response may help explain the typical absence of overt signs of inflammation among women with BV. In addition, hormonal contraceptive use was associated with significantly lower levels of the pro-inflammatory molecules TNF, interferon-gamma, and granulocyte macrophage colony-stimulating factor in women with BV, but did not significantly reduce the levels of IL-10, a key anti-inflammatory cytokine. These results suggest the possibility of an association between hormonal contraceptive use and altered genital tract immunity.
Authors: Michelle C Sabo; Dara A Lehman; Bingjie Wang; Barbra A Richardson; Sujatha Srinivasan; Lusi Osborn; Daniel Matemo; John Kinuthia; Tina L Fiedler; Matthew M Munch; Alison L Drake; David N Fredricks; Julie Overbaugh; Grace John-Stewart; R Scott McClelland; Susan M Graham Journal: Sex Transm Infect Date: 2019-06-13 Impact factor: 3.519
Authors: Charles S Morrison; Pai-Lien Chen; Cynthia Kwok; Barbra A Richardson; Tsungai Chipato; Roy Mugerwa; Josaphat Byamugisha; Nancy Padian; David D Celentano; Robert A Salata Journal: AIDS Date: 2010-07-17 Impact factor: 4.177
Authors: Tessa Madden; Jaclyn M Grentzer; Gina M Secura; Jenifer E Allsworth; Jeffrey F Peipert Journal: Sex Transm Dis Date: 2012-03 Impact factor: 2.830
Authors: Andrea Ries Thurman; Thomas Kimble; Betsy Herold; Pedro M M Mesquita; Raina N Fichorova; Hassan Y Dawood; Titilayo Fashemi; Neelima Chandra; Lorna Rabe; Tina D Cunningham; Sharon Anderson; Jill Schwartz; Gustavo Doncel Journal: AIDS Res Hum Retroviruses Date: 2015-07-23 Impact factor: 2.205
Authors: Brenna L Anderson; Hector Mendez-Figueroa; Joshua D Dahlke; Christina Raker; Sharon L Hillier; Susan Cu-Uvin Journal: Am J Obstet Gynecol Date: 2013-01-10 Impact factor: 8.661
Authors: Catriona S Bradshaw; Jennifer Walker; Christopher K Fairley; Marcus Y Chen; Sepehr N Tabrizi; Basil Donovan; John M Kaldor; Kathryn McNamee; Eve Urban; Sandra Walker; Marian Currie; Hudson Birden; Francis Bowden; Suzanne Garland; Marie Pirotta; Lyle Gurrin; Jane S Hocking Journal: PLoS One Date: 2013-03-05 Impact factor: 3.240